Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 8/20 | 0.73 |
| ▸ | TSHR | P16473 | 6/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 8/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.70 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723441 | 0.87 | PRMT1 (0.74) | HTTTSHRSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL17933850 | 0.83 | HTT (0.76) | HTTTSHRSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL34460852 | 0.83 | HTT (1.00) | HTTTSHRSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL30320062 | 0.81 | PRMT1 (0.65) | HTTTSHRSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL4913787 | 0.78 | RAB9A (0.72) | HTTTSHRSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL4914387 | 0.77 | LMNA (0.63) | HTTTSHRSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL12788030 | 0.77 | TP53 (0.60) | HTTTSHRSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL29141649 | 0.76 | BRD4 (0.62) | HTTTSHRSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL4921531 | 0.76 | PRMT1 (0.72) | HTTTSHRSMN1; SMN2HSD17B10MAPT | |
| SCHEMBL29827200 | 0.76 | CDC7 (0.69) | HTTTSHRSMN1; SMN2HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4115882-A1 | COMPOUNDS FOR IMPROVING MRNA SPLICING | The General Hospital Corporation (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | HTT 326/4885TSHR 4371/4885SMN1; SMN2 11/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | HTT 326/4885TSHR 4371/4885SMN1; SMN2 11/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | HTT 326/4885TSHR 4371/4885SMN1; SMN2 11/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | HTT 326/4885TSHR 4371/4885SMN1; SMN2 11/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | HTT 326/4885TSHR 4371/4885SMN1; SMN2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.